Krystal Biotech (KRYS) Amortization of Deferred Charges (2023 - 2026)
Krystal Biotech (KRYS) reported Amortization of Deferred Charges of $204000.0 for Q1 2026, down 8.93% on a YoY basis from $224000.0 in Q1 2025, and up 2.0% sequentially from $200000.0 in Q4 2025.
Krystal Biotech (KRYS) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Krystal Biotech (KRYS) has 4 years of Amortization of Deferred Charges data on file, last reported at $204000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 8.93% year-over-year to $204000.0; the trailing twelve-month figure through Mar 2026 stood at $807000.0 (up 2.28% YoY), and the FY2025 full-year result was $827000.0, up 10.71% from the prior year.
- Amortization of Deferred Charges advanced to $204000.0 in Q1 2026, from $200000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $233000.0 in Q4 2023 to a low of $182000.0 in Q1 2024.
- A 4-year average of $206307.7 and a median of $204000.0 in 2026 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges retreated 18.26% in 2024 and rose 23.08% in 2025, its largest moves.
- Tracing KRYS's Amortization of Deferred Charges over 4 years: stood at $233000.0 in 2023, then dropped by 18.03% to $191000.0 in 2024, then increased by 4.71% to $200000.0 in 2025, then gained by 2.0% to $204000.0 in 2026.
- Business Quant data shows KRYS's Amortization of Deferred Charges at $204000.0 in Q1 2026, $200000.0 in Q4 2025, and $209000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Krystal Biotech | 9.88 Bn | 9.06 Bn | 110.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 233,000.00 |
| Dec 31, 2023 | 233,000.00 |